Tokyo, June 5, 2006 (JCN) - Dainippon Sumitomo Pharma has signed a licensing agreement with US pharmaceutical company Chelsea Therapeutics International.
Under the agreement terms, Chelsea Therapeutics International will receive exclusive rights to develop and sell Dops, Dainippon Sumitomo Pharma's proprietary agent, worldwide except in Japan, China, South Korea and Taiwan.
In Japan, Dops, which is a precursor of norepinephrine, is currently available for the treatment of frozen gait and dizziness associated with Parkinson's disease, and vertigo, dizziness and fatigue associated with orthostatic hypotension in hemodialysis patients.
Going forward, Chelsea Therapeutics International will develop the agent as an orphan drug for the treatment of orthostatic hypotension associated with autonomic disorder.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore
(Jan 22, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent
(Dec 28, 2012)
|
|
|
NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area
(Oct 23, 2008)
|
|
|
Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug
(May 8, 2008)
|
|
|
Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic
(Dec 13, 2006)
|
|
|
Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent
(Nov 28, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs
(July 26, 2006)
|
|
|
Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection
(June 16, 2006)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Drugs & OTC news...
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Drugs & OTC news...
|
|
